Recombinant Nipah Virus Post-Fusion Glycoprotein (NIV pF) anticorps

N° du produit ABIN7824739

Cet anticorps Souris Monoclonal détecte spécifiquement dans ELISA et WB. Il présente une réactivité envers Nipah Virus (NiV).

Aperçu rapide pour Recombinant Nipah Virus Post-Fusion Glycoprotein (NIV pF) anticorps (ABIN7824739)

Antigène: Nipah Virus Post-Fusion Glycoprotein (NIV pF)

Type d'anticorp: Recombinant Antibody

Reactivité: Nipah Virus (NiV)

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Inconjugué

Application: ELISA, Western Blotting (WB)

Clone: 3C3

Détail du produit

Expression System: HEK293

Fonction: Monoclonal Anti-Nipah Post Fusion glycoprotein Antibody, Human IgG1 (3C3) (MALS verified)

Attributs du produit: Monoclonal Anti-Nipah Post Fusion glycoprotein Antibody, Human IgG1 (3C3) is a chimeric monoclonal antibody recombinantly expressed from HEK293, which combines the variable region of a mouse monoclonal antibody with Human constant domain.

Purification: Protein A purified / Protein G purified

Pureté: 95% as determined by SDS-PAGE.

Stérilité: 0.22 μm filtered

Isotype: IgG1, kappa

Information d'application

Indications d'application: ELISA: 0.03-16 ng/ml; Western Blot: 0.05-10 µg/ml

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Buffer: Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Conseil sur la manipulation: Please avoid repeated freeze-thaw cycles.

Stock: -20 °C,-80 °C

Stockage commentaire: For long term storage, the product should be stored at lyophilized state at -20°C or lower. This product is stable after storage at: -20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution.

Détail du antigène

Antigène: Nipah Virus Post-Fusion Glycoprotein (NIV pF)

Autre désignation: Nipah Virus Post-Fusion Glycoprotein

Sujet: Hendra virus (HeV) and Nipah virus (NiV) are henipaviruses discovered in the mid-to late 1990s that possess a broad host tropism and are known to cause severe and often fatal disease in both humans and animals. HeV and NiV infect host cells through the coordinated efforts of two envelope glycoproteins. The G glycoprotein attaches to cell receptors, triggering the fusion (F) glycoprotein to execute membrane fusion. G is a type II homotetrameric transmembrane protein responsible for binding to ephrinB2 or ephrinB3 (ephrinB2/B3) receptors. F is a homotrimeric type I transmembrane protein that is synthesized as a premature F0 precursor and cleaved by cathepsin L during endocytic recycling to yield the mature, disulfide-linked, F1 and F2 subunits. Upon binding to ephrinB2/B3, NiV G undergoes conformational changes leading to F triggering and insertion of the F hydrophobic fusion peptide into the target membrane. Subsequent refolding into the more stable post-fusion F conformation drives merger of the viral and host membranes to form a pore for genome delivery to the cell cytoplasm.